Literature DB >> 11181524

Lysophosphatidic acid is an osteoblast mitogen whose proliferative actions involve G(i) proteins and protein kinase C, but not P42/44 mitogen-activated protein kinases.

A Grey1, T Banovic, D Naot, B Hill, K Callon, I Reid, J Cornish.   

Abstract

The simple glycerophospholipid lysophosphatidic acid (LPA) acts both as an intermediary in phospholipid metabolism and as an intercellular signaling molecule in its own right. In various cell types, LPA signals through its membrane-bound, G protein-coupled receptors to influence cellular processes such as proliferation, survival, and cytoskeletal function. Its actions in bone cells have not been studied. Here we show that the LPA receptor, LP(A1)/edg-2/vzg-1, is expressed in primary rat osteoblasts and the UMR 106-01 osteoblastic cell line. LPA potently induces DNA synthesis and an increase in cell number in cultures of osteoblastic cells. LPA rapidly (within 10 min) stimulates phosphorylation of p42/44 mitogen-activated protein (MAP) kinases in osteoblastic cells, an effect that is sensitive to inhibition of G(i) proteins, inhibition of influx of extracellular calcium, and inhibition of protein kinase C. LPA-induced DNA synthesis is partially inhibited by either pertussis toxin or calphostin C, but is insensitive to specific inhibitors of MEK, the kinase upstream of p42/44 MAP kinases, or of phosphatidylinositol-3 kinases. These data demonstrate that LPA is an osteoblast mitogen whose signaling effects in osteoblastic cells include activation of p42/44 MAP kinases. However, the LPA mitogenic signal in osteoblastic cells, while requiring G(i) proteins and protein kinase C, is independent of the activity of p42/44 MAP kinases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11181524     DOI: 10.1210/endo.142.3.8011

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  15 in total

1.  Regulation of gene expression and subcellular protein distribution in MLO-Y4 osteocytic cells by lysophosphatidic acid: Relevance to dendrite outgrowth.

Authors:  Katrina M Waters; Jon M Jacobs; Marina A Gritsenko; Norman J Karin
Journal:  Bone       Date:  2011-02-26       Impact factor: 4.398

Review 2.  [Research progress on the biological regulatory function of lysophosphatidic acid in bone tissue cells].

Authors:  Xiang-Nan Wu; Yuan-Yuan Ma; Zhi-Chao Hao; Hang Wang
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2020-06-01

3.  Lysophosphatidic acid signals through multiple receptors in osteoclasts to elevate cytosolic calcium concentration, evoke retraction, and promote cell survival.

Authors:  Danielle M Lapierre; Natsuko Tanabe; Alexey Pereverzev; Martha Spencer; Ryan P P Shugg; S Jeffrey Dixon; Stephen M Sims
Journal:  J Biol Chem       Date:  2010-06-15       Impact factor: 5.157

4.  Phospholipases of mineralization competent cells and matrix vesicles: roles in physiological and pathological mineralizations.

Authors:  Saida Mebarek; Abdelkarim Abousalham; David Magne; Le Duy Do; Joanna Bandorowicz-Pikula; Slawomir Pikula; René Buchet
Journal:  Int J Mol Sci       Date:  2013-03-01       Impact factor: 5.923

5.  Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts.

Authors:  Marion David; Estelle Wannecq; Françoise Descotes; Silvia Jansen; Blandine Deux; Johnny Ribeiro; Claire-Marie Serre; Sandra Grès; Nathalie Bendriss-Vermare; Mathieu Bollen; Simone Saez; Junken Aoki; Jean-Sébastien Saulnier-Blache; Philippe Clézardin; Olivier Peyruchaud
Journal:  PLoS One       Date:  2010-03-17       Impact factor: 3.240

Review 6.  Aiming drug discovery at lysophosphatidic acid targets.

Authors:  Gabor Tigyi
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

7.  Bone marrow mesenchymal stem cells are abnormal in multiple myeloma.

Authors:  J Corre; K Mahtouk; M Attal; M Gadelorge; A Huynh; S Fleury-Cappellesso; C Danho; P Laharrague; B Klein; T Rème; P Bourin
Journal:  Leukemia       Date:  2007-03-08       Impact factor: 11.528

8.  Absence of the lysophosphatidic acid receptor LPA1 results in abnormal bone development and decreased bone mass.

Authors:  Isabelle Gennero; Sara Laurencin-Dalicieux; Françoise Conte-Auriol; Fabienne Briand-Mésange; Danielle Laurencin; Jackie Rue; Nicolas Beton; Nicole Malet; Marianne Mus; Akira Tokumura; Philippe Bourin; Laurence Vico; Gérard Brunel; Richard O C Oreffo; Jerold Chun; Jean Pierre Salles
Journal:  Bone       Date:  2011-05-01       Impact factor: 4.398

9.  Polymorphisms in the P2X7 receptor gene are associated with low lumbar spine bone mineral density and accelerated bone loss in post-menopausal women.

Authors:  Alison Gartland; Kristen K Skarratt; Lynne J Hocking; Claire Parsons; Leanne Stokes; Niklas Rye Jørgensen; William D Fraser; David M Reid; James A Gallagher; James S Wiley
Journal:  Eur J Hum Genet       Date:  2012-01-11       Impact factor: 4.246

10.  Blockade of receptor-activated G(i) signaling in osteoblasts in vivo leads to site-specific increases in cortical and cancellous bone formation.

Authors:  Susan M Millard; Alyssa M Louie; Lalita Wattanachanya; Thomas J Wronski; Bruce R Conklin; Robert A Nissenson
Journal:  J Bone Miner Res       Date:  2011-04       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.